EXEL
$EXEL
Exelixis, Inc.
Oncology-focused biotech company with Cabometyx for kidney and liver cancers.
HealthcareSubscribers
0
Tracking this ticker
Next Report
Sun, Mar 22
Weekly updates
Latest Report
EXEL: Stable Cash Flows, Modest Upside
Exelixis (EXEL) posts strong profitability and cash generation, with a Buy consensus from analysts but limited upside to mean price targets. Upcoming May earnings and pipeline updates will be key catalysts.
Mar 16, 2026